UCB Sells Anti-Haemorrhagic Drug To Eumedica

Main Category: Pharma Industry / Biotech Industry
Also Included In: Blood / Hematology;  GastroIntestinal / Gastroenterology
Article Date: 12 Feb 2009 - 0:00 PDT

email to a friend   printer friendly   view / write opinions

UCB focuses on indications in central nervous system (CNS) and immunology, in-line with its SHAPE programme

Brussels (Belgium), February 10, 2009 at 6:00 PM (CET) - press release, regulated information - UCB announced today that it has agreed to sell world-wide rights to its anti-haemorrhagic product Somatostatine-UCB™ to Eumedica.

Somatostatine-UCB™ is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other. Somatostatine-UCB™ is being used in hospitals in more than 25 markets worldwide, for more than 20 years, especially in Western Europe. UCB's world-wide 2008 net sales of Somatostatine-UCB™ were approx. EUR 11.4 million. UCB receives a cash consideration of an industry average sales multiple for established products. Further details of the agreement are not disclosed.

About UCB

UCB, Brussels, Belgium is a global biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10 000 people in over 40 countries, UCB expects to achieve revenue of at least 3.3 billion Euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

UCB

About Eumedica

Eumedica is a niche pharma group, created in 1986, focusing on pharmaceutical products responding to urgent medical needs. The group is mainly present in the Benelux, France, the United Kingdom, Italy and Switzerland and expects to achieve a turnover of EUR 43.6 million in 2008. The distribution of Somatostatine-UCB will be organized from the new worldwide logistical center of the group in Manage, Belgium.

Eumedica

Forward Looking Statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

Eumedica